Chembio Diagnostics, Inc.
CEMI · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $48,340 | $36,927 | $30,451 | $34,464 |
| % Growth | 30.9% | 21.3% | -11.6% | – |
| Cost of Goods Sold | $38,578 | $34,496 | $23,874 | $22,394 |
| Gross Profit | $9,762 | $2,431 | $6,577 | $12,070 |
| % Margin | 20.2% | 6.6% | 21.6% | 35% |
| R&D Expenses | $7,068 | $12,487 | $9,508 | $8,538 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $24,278 | $24,841 | $21,038 | $16,138 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1,182 | -$10,892 | -$2,019 | $0 |
| Operating Expenses | $30,164 | $26,436 | $28,527 | $24,677 |
| Operating Income | -$20,402 | -$24,005 | -$21,950 | -$12,607 |
| % Margin | -42.2% | -65% | -72.1% | -36.6% |
| Other Income/Exp. Net | $382 | -$9,960 | -$2,842 | -$847 |
| Pre-Tax Income | -$23,256 | -$33,966 | -$25,978 | -$14,175 |
| Tax Expense | $34 | -$62 | -$457 | -$500 |
| Net Income | -$23,291 | -$33,904 | -$25,521 | -$13,675 |
| % Margin | -48.2% | -91.8% | -83.8% | -39.7% |
| EPS | -0.96 | -1.4 | -1.34 | -0.81 |
| % Growth | 31.4% | -4.5% | -65.4% | – |
| EPS Diluted | -0.96 | -1.4 | -1.34 | -0.81 |
| Weighted Avg Shares Out | 24,299 | 24,299 | 19,086 | 16,954 |
| Weighted Avg Shares Out Dil | 24,299 | 24,299 | 19,086 | 16,954 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $847 |
| Interest Expense | $382 | $2,912 | $2,842 | $846,831 |
| Depreciation & Amortization | $5,789 | $2,931 | $2,697 | $721 |
| EBITDA | -$14,613 | -$21,074 | -$19,253 | -$861,006 |
| % Margin | -30.2% | -57.1% | -63.2% | -2,498.3% |